Indication
Relapse/Refractory Multiple Myeloma
3 clinical trials
5 products
Product
ATG-010Product
CYAD-211Clinical trial
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory DiseaseStatus: Active (not recruiting), Estimated PCD: 2022-12-21
Product
FludaraProduct
EndoxanClinical trial
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome InhibitorStatus: Completed, Estimated PCD: 2022-02-25
Clinical trial
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-20